ICOTYDE meets primary endpoint in Phase 3 psoriatic arthritis trial

Johnson & Johnson presented Phase 3 ICONIC-PsA 1 results for its oral IL-23 receptor blocker ICOTYDE (icotrokinra) at the ACR Convergence 2026 meeting, where the study hit its primary endpoint at week 16 in biologic-naive adults with active psoriatic arthritis. The 200 mg dose delivered higher ACR20, ACR50 and ACR70 response rates than placebo, and skin clearance outcomes were also well ahead of control. Week 24 data showed responses continuing to build with no new safety signals. The company also shared Phase 2 DAHLIAS data for nipocalimab in Sjogren's disease, where dry mouth was the symptom most patients named as their top complaint, and it has moved that program into a Phase 3 study.

1. ICOTYDE (icotrokinra) met its primary endpoint at week 16 in the Phase 3 ICONIC-PsA 1 study of biologic-naive adults with active psoriatic arthritis.
2. At the 200 mg dose, about 58% of patients reached ACR20 versus 41% on placebo; ACR50 was 29% versus 16% and ACR70 was 13% versus 5%.
3. Among patients with qualifying skin involvement, 57% on ICOTYDE reached clear or almost clear skin versus 14% on placebo; PASI 90 was 37% versus 6%.
4. At week 24, ACR20 response reached 69% and ACR50 reached 40%; the company reported no new safety signals over 24 weeks.
5. Phase 2 DAHLIAS data for nipocalimab in Sjogren's disease: 96% of patients cited dry mouth as their primary complaint; the Phase 3 DAFFODIL trial has since launched.
6. Data were presented at the American College of Rheumatology (ACR) Convergence 2026 meeting, reported on November 9, 2026.